[
    [
        {
            "time": "2018-10-02",
            "original_text": "Health Care Sector Update for 10/02/2018: MMSI,JNJ,LLY",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "MMSI",
                    "JNJ",
                    "LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 10/02/2018: MMSI,JNJ,LLY",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "Examining the Performances of Eli Lilly’s Oncology Products",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Oncology Products"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Examining the Performances of Eli Lilly’s Oncology Products",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "Health Care Sector Update for 10/02/2018: JNJ,LLY",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "JNJ",
                    "LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 10/02/2018: JNJ,LLY",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "How Eli Lilly’s Cardiovascular Products Have Been Faring",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Cardiovascular Products"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "How Eli Lilly’s Cardiovascular Products Have Been Faring",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "Migraine sufferers: Help is on the way from 3 new drugs, but they’ll cost $6,900 a year",
            "features": {
                "keywords": [
                    "Migraine",
                    "drugs",
                    "cost"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Migraine sufferers: Help is on the way from 3 new drugs, but they’ll cost $6,900 a year",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
            "features": {
                "keywords": [
                    "IHS Markit Score",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "Stocks making the biggest move premarket: PEP, AMZN, SFIX, CVX & more",
            "features": {
                "keywords": [
                    "Stocks",
                    "premarket",
                    "PEP",
                    "AMZN",
                    "SFIX",
                    "CVX"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "various"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Stocks making the biggest move premarket: PEP, AMZN, SFIX, CVX & more",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "Does Mylan’s Low Valuation Provide a ‘Buy’ Opportunity?",
            "features": {
                "keywords": [
                    "Mylan",
                    "Low Valuation",
                    "Buy Opportunity"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Does Mylan’s Low Valuation Provide a ‘Buy’ Opportunity?",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "A Closer Look at Eli Lilly’s Human Pharmaceutical Business",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Human Pharmaceutical Business"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A Closer Look at Eli Lilly’s Human Pharmaceutical Business",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "Eli Lilly's diabetes treatment meets main goal in two late-stage studies",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "diabetes treatment",
                    "late-stage studies"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly's diabetes treatment meets main goal in two late-stage studies",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes",
            "features": {
                "keywords": [
                    "Phase 3 Studies",
                    "Lilly",
                    "Ultra Rapid Lispro",
                    "Type 1",
                    "Type 2 Diabetes"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "Eli Lilly: Phase 3 Studies Show URLi Meets Primary Efficacy Endpoint",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Phase 3 Studies",
                    "URLi",
                    "Primary Efficacy Endpoint"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly: Phase 3 Studies Show URLi Meets Primary Efficacy Endpoint",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]